c-IAP1 and c-IAP2: inhibitors of apoptosis
AssigneeTularik Inc.
InventorsMike Rothe, David V. Goeddel
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular, at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis; for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes.
Claims17
An isolated nucleic acid comprising the sequence set forth by nucleotides 1053-1196 of SEQ ID NO:
- 1.
An isolated nucleic acid comprising the sequence set forth by SEQ ID NO:
- 3.
An isolated nucleic acid encoding a human cellular inhibitor of apoptosis protein (c-IAP) comprising the sequence set forth by residues 287-334 of SEQ ID NO:
- 2.
An isolated nucleic acid encoding a human cellular inhibitor of apoptosis protein (c-IAP) comprising the sequence set forth by SEQ ID NO:
- 4.
An isolated nucleic acid encoding a human cellular inhibitor of apoptosis protein (c-IAP) comprising at least two of:
- a first domain comprising SEQ ID NO:
- 5 or 6, a second domain comprising SEQ ID NO:
- 7 or 8, and a third domain comprising SEQ ID NO:
- 9 or 10.
Dependencies are inferred from the claim text.